Ledipasvir
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Ledipasvir: Repurposing Evaluation — Insufficient Data to Complete Assessment
One-Sentence Summary
Ledipasvir (DB09027) is a small molecule drug currently under initial repurposing evaluation. This Evidence Pack contains no TxGNN predicted indications, and both original indication and mechanism of action data are absent from the current dataset. A full repurposing report cannot be generated until critical data gaps are resolved.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in current dataset |
| Predicted New Indication | None — no TxGNN predictions in this Evidence Pack |
| TxGNN Prediction Score | N/A |
| Evidence Level | N/A (no predictions available) |
| Finland Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: This Evidence Pack contains no TxGNN model predictions and has blocking-severity data gaps in MOA and safety information; a repurposing evaluation cannot be meaningfully conducted at this stage.
To proceed, the following is needed:
- [Blocking] Retrieve TFDA package insert warnings and contraindications to enable basic safety screening
- [High] Obtain mechanism of action (MOA) data from DrugBank (DB09027) to support mechanistic plausibility analysis
- [Required] Re-run TxGNN prediction pipeline for ledipasvir to generate candidate indications
- [Required] Populate original indication data (ledipasvir is expected to have registered HCV indications in other markets — confirm and import)
- [Required] After predictions are available, re-query clinical trial (ClinicalTrials.gov) and literature (PubMed) evidence for each candidate indication
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.